Drug Profile
Research programme: influenza A virus vaccines - AmVac
Alternative Names: AMV 411; Influenza A virus H5N1 vaccine - National Health Research Institutes/AmVac; Influenza A virus infections vaccine - AmVac; Prophylactic pandemic influenza vaccine - AmVacLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator AmVac
- Class Influenza A vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-A-virus-infections(Prevention) in Switzerland (Intranasal, Spray)
- 02 Dec 2014 Preclinical development is ongoing in Switzerland
- 20 Jun 2013 Preclinical trials of AMV 411 in Influenza-A virus infections (prevention) in Switzerland (Intranasal)